Coherus BioSciences Inc (CHRS)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $81.21M
Last updated: Nov 17, 2026 at 11:04 AM ET
Coherus BioSciences Inc (CHRS) Earnings: Report Dates and Results
Coherus BioSciences (CHRS) is expected to report earnings on Mar 8, 2027. In the quarter ended Sep 30, 2026, Coherus BioSciences reported EPS of -$0.25, below the -$0.22 estimate. It beat the EPS estimate in 1 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
CHRS has an expected report date of Mar 8, 2027.
CHRS Earnings Call
The latest CHRS earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, CHRS beat 11, missed 28 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $14.27M, up 23.3% from $11.57M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.25 | -$0.22 | N/A | -13.64% | Miss | N/A | 1 | 2 up, 0 down | Nov 9, 2026 | $14.27M |
| Jun 30, 2026 | -$0.22 | -$0.16 | -$0.31 - $0.08 | -37.50% | Miss | N/A | 2 | 2 up, 0 down | Aug 5, 2026 | $14.31M |
| Mar 31, 2026 | -$0.25 | -$0.26 | -$0.35 - -$0.18 | +3.85% | Beat | N/A | 2 | 0 up, 0 down | May 11, 2026 | $12.31M |
| Dec 31, 2025 | -$0.34 | -$0.34 | N/A | -0.53% | Miss | N/A | 1 | 0 up, 1 down | Mar 9, 2026 | $12.75M |
| Sep 30, 2025 | -$0.33 | -$0.29 | -$0.32 - -$0.26 | -13.79% | Miss | N/A | 2 | 0 up, 1 down | Nov 6, 2025 | $11.57M |
| Jun 30, 2025 | -$0.39 | -$0.25 | -$0.33 - -$0.17 | -56.00% | Miss | N/A | 3 | 0 up, 1 down | Aug 7, 2025 | $10.25M |
| Mar 31, 2025 | -$0.35 | -$0.22 | N/A | -59.09% | Miss | N/A | 2 | 0 up, 0 down | May 12, 2025 | $7.60M |
| Dec 31, 2024 | -$0.28 | -$0.13 | -$0.23 - $0.06 | -114.56% | Miss | N/A | 5 | 0 up, 1 down | Mar 10, 2025 | $7.73M |
| Sep 30, 2024 | -$0.01 | -$0.11 | -$0.28 - $0.02 | +90.91% | Beat | N/A | 5 | 2 up, 0 down | Nov 6, 2024 | $6.05M |
| Jun 30, 2024 | -$0.14 | -$0.26 | -$0.38 - -$0.23 | +46.15% | Beat | N/A | 3 | 1 up, 0 down | Aug 8, 2024 | $10.30M |
| Mar 31, 2024 | -$0.32 | -$0.21 | -$0.37 - -$0.05 | -52.38% | Miss | N/A | 5 | 0 up, 0 down | May 9, 2024 | $2.31M |
| Dec 31, 2023 | -$0.62 | -$0.12 | -$0.37 - $0.52 | -416.67% | Miss | N/A | 6 | 1 up, 0 down | Mar 13, 2024 | $91.52M |
| Sep 30, 2023 | -$0.27 | -$0.24 | -$0.67 - $0.03 | -12.50% | Miss | N/A | 7 | 0 up, 0 down | Nov 6, 2023 | $74.57M |
| Jun 30, 2023 | -$0.38 | -$0.44 | -$0.61 - -$0.21 | +13.64% | Beat | N/A | 7 | 3 up, 0 down | Aug 2, 2023 | $58.72M |
| Mar 31, 2023 | -$0.80 | -$0.47 | -$1.00 - -$0.18 | -70.21% | Miss | N/A | 7 | 3 up, 0 down | May 8, 2023 | $32.44M |
| Dec 31, 2022 | -$0.60 | -$0.84 | -$1.52 - -$0.62 | +28.57% | Beat | N/A | 6 | 0 up, 0 down | Mar 6, 2023 | $45.35M |
| Sep 30, 2022 | -$0.96 | -$0.61 | -$0.68 - -$0.48 | -57.38% | Miss | N/A | 5 | 2 up, 0 down | Nov 8, 2022 | $45.42M |
| Jun 30, 2022 | -$0.47 | -$0.73 | -$0.79 - -$0.49 | +35.62% | Beat | N/A | 5 | 1 up, 0 down | Aug 4, 2022 | $60.15M |
| Mar 31, 2022 | -$1.00 | -$0.65 | N/A | -53.85% | Miss | N/A | 4 | 0 up, 1 down | May 5, 2022 | $60.12M |
| Dec 31, 2021 | -$0.60 | -$0.54 | -$0.79 - -$0.25 | -11.11% | Miss | -600.0% | 5 | N/A | Feb 17, 2022 | $73.37M |
| Sep 30, 2021 | -$0.49 | -$0.29 | -$0.30 - -$0.13 | -68.97% | Miss | -248.5% | 5 | N/A | Nov 8, 2021 | $82.50M |
| Jun 30, 2021 | -$0.40 | -$0.15 | -$0.25 - -$0.05 | -166.67% | Miss | -157.1% | 4 | N/A | Aug 5, 2021 | $87.64M |
| Mar 31, 2021 | -$0.23 | $0.11 | -$0.03 - $0.13 | -309.09% | Miss | -147.9% | 6 | N/A | May 6, 2021 | $83.03M |
| Dec 31, 2020 | $0.12 | $0.23 | $0.13 - $0.40 | -47.83% | Miss | -78.6% | 10 | N/A | Feb 24, 2021 | $110.42M |
| Sep 30, 2020 | $0.33 | $0.34 | $0.23 - $0.76 | -2.94% | Miss | -47.6% | 10 | N/A | Nov 5, 2020 | $113.55M |
| Jun 30, 2020 | $0.70 | $0.29 | $0.20 - $0.73 | +141.38% | Beat | +118.7% | 9 | N/A | Aug 6, 2020 | $135.67M |
| Mar 31, 2020 | $0.48 | $0.48 | $0.36 - $0.74 | 0.00% | In line | N/A | 8 | N/A | May 7, 2020 | $116.18M |
| Dec 31, 2019 | $0.56 | $0.72 | $0.64 - $0.82 | -22.22% | Miss | N/A | 8 | N/A | Feb 27, 2020 | $123.86M |
| Sep 30, 2019 | $0.63 | $0.42 | $0.28 - $0.83 | +50.00% | Beat | N/A | 8 | N/A | Nov 6, 2019 | $111.68M |
| Jun 30, 2019 | $0.32 | -$0.04 | -$0.36 - $0.29 | +900.00% | Beat | N/A | 7 | N/A | Aug 1, 2019 | $83.43M |
| Mar 31, 2019 | -$0.29 | -$0.46 | -$0.52 - -$0.38 | +36.96% | Beat | N/A | 6 | N/A | May 9, 2019 | $37.10M |
| Dec 31, 2018 | -$0.92 | -$0.86 | -$0.90 - -$0.81 | -6.98% | Miss | N/A | 4 | N/A | Feb 28, 2019 | N/A |
| Sep 30, 2018 | -$0.87 | -$0.79 | -$0.82 - -$0.70 | -10.13% | Miss | N/A | 5 | N/A | Nov 8, 2018 | N/A |
| Jun 30, 2018 | -$0.68 | -$0.65 | -$0.76 - -$0.53 | -4.62% | Miss | N/A | 5 | N/A | Aug 8, 2018 | N/A |
| Mar 31, 2018 | -$0.74 | -$0.70 | -$0.85 - -$0.55 | -5.71% | Miss | N/A | 5 | N/A | May 10, 2018 | N/A |
| Dec 31, 2017 | -$0.84 | -$0.81 | -$1.03 - -$0.49 | -3.70% | Miss | N/A | 6 | N/A | Mar 8, 2018 | $1.56M |
| Sep 30, 2017 | -$1.09 | -$0.85 | N/A | -28.24% | Miss | -165.3% | N/A | N/A | Nov 6, 2017 | N/A |
| Jun 30, 2017 | -$1.08 | -$1.39 | N/A | +22.30% | Beat | N/A | N/A | N/A | Aug 7, 2017 | $1.40M |
| Mar 31, 2017 | -$1.54 | -$1.43 | N/A | -7.69% | Miss | N/A | N/A | N/A | May 8, 2017 | $161000 |
| Dec 31, 2016 | -$1.71 | -$1.11 | N/A | -54.05% | Miss | N/A | N/A | N/A | Mar 13, 2017 | $844000 |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$1.41, after -$0.75 the year before. It was -$3.43 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$1.41 | N/A |
| Dec 31, 2024 | -$0.75 | N/A |
| Dec 31, 2023 | -$2.07 | N/A |
| Dec 31, 2022 | -$3.03 | N/A |
| Dec 31, 2021 | -$1.72 | -205.5% |
| Dec 31, 2020 | $1.63 | +33.6% |
| Dec 31, 2019 | $1.22 | N/A |
| Dec 31, 2018 | -$3.21 | N/A |
| Dec 31, 2017 | -$4.55 | N/A |
| Dec 31, 2016 | -$3.43 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 6,300 words across 12 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 6,259 | 12 | |
| 2026Q2 | Jun 30, 2026 | 5,733 | 12 | |
| 2026Q1 | Mar 31, 2026 | 6,275 | 13 | |
| 2025Q4 | Dec 31, 2025 | 7,705 | 12 | |
| 2025Q3 | Sep 30, 2025 | 6,783 | 13 | |
| 2025Q2 | Jun 30, 2025 | 6,212 | 13 | |
| 2025Q1 | Mar 31, 2025 | 7,760 | 12 | |
| 2024Q4 | Dec 31, 2024 | 6,818 | 14 |
2026Q3 Earnings Call
Opening remarks
Carrie Graham Investor Relations Thank you, Heidi. Third quarter earnings conference call. Joining me are Denny Lanfear, Chief Executive Officer of Coherus; Dr. Rosh Dias, Chief Medical Officer; Dr. Theresa Lavallee, Chief Scientific and Development Officer; Sameer Goregaoker, Chief Commercial Officer; and Bryan McMichael, Chief Financial Officer. Before we get started, I would like to remind you that today's call includes forward-looking statements regarding Coherus' current expectations about future events. Actual results may vary significantly, and we undertake no duty to update or revise any forward-looking statements. Please see the press release that we issued today and our quarterly report on Form 10-Q for more information on risks and uncertainties. And now I'll turn the call over to Denny.
Dennis Lanfear CEO Thank you, Carrie, and good afternoon, everyone. Thank you for joining us on our third quarter 2026 earnings call. As you know, we have spent the last few years transforming Coherus from a biosimilars company into an innovative oncology company focused on overcoming immune resistance in cancer. We've made substantial progress in reducing our debt, lowering our operating expenses, establishing LOQTORZI in the market, and advancing our clinical pipeline. We've conducted key clinical trials and developed sufficient data to set future development direction for our tagmokitug program and select the go-forward dose. Today, I will discuss three strategic alternatives designed to make Coherus a financially self-sustaining innovative oncology company with best-in-class and first-in-class products by the end of 2027. First, the strategic prioritization of esophageal cancer as our focus for best-in-disease development of tagmokitug. Second, the structural and financial benefits that flow directly from this prioritization. And then finally, our emphasis on driving LOQTORZI revenues over the next four or five quarters to a level where they can fully support the company's core cash burn. When we launched the tagmokitug clinical program, it was with a clear expectation that we would select the most promising area for continued development. This is exactly what we have done. As we reported on October 28, over the last two years, we have explored a wide range of mucosal system cancers, from head and neck, esophageal, gastric, and colorectal, across various lines of therapy to understand where Treg depletion might best be advanced as combination therapy. The emerging data from this very systematic clinical investigation demonstrated that esophageal cancer comprises a best-in-disease opportunity across first and second lines of therapy. Accordingly, going forward, we will be sharply focusing our tagmokitug development efforts there, as this provides a substantial number of benefits. First, providing a treatment alternative to patients confronting a particularly difficult cancer with poor prognosis.
Frequently Asked Questions About CHRS
When is Coherus BioSciences's next earnings date?
Coherus BioSciences's next earnings report is expected for Mar 8, 2027.
Did CHRS beat earnings estimates last quarter?
No. Coherus BioSciences reported EPS of -$0.25 for the quarter ended Sep 30, 2026, below the -$0.22 estimate by 13.64%.
What EPS do analysts expect from CHRS next quarter?
The consensus EPS estimate for Coherus BioSciences for the quarter ending Dec 31, 2026 is -$0.22 from 9 analysts, with estimates from -$0.28 to -$0.19.
How often does CHRS beat earnings estimates?
Coherus BioSciences beat the EPS estimate in 1 of the last 8 quarters, with an average surprise of -36.41%.
CHRS pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors